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A B S T R A C T
Background: Non-motor symptoms (NMSs) are clearly more prevalent in Parkinson's disease (PD) patients
compared to healthy individuals. However, NMSs are also common in the elderly and other neurological con-
ditions, and thus, it is not known whether NMSs could be used to differentiate PD from parkinsonism/tremor
without dopamine deficiency.
Methods: We prospectively evaluated NMSs immediately before brain dopamine transporter (DAT) [123I]FP-CIT
SPECT scanning in 193 patients with unclear parkinsonism/tremor. According to the clinical follow-up and
imaging results, 84 patients had PD. NMSs and their correlations with striatal DAT binding were investigated in
PD patients and in parkinsonism/tremor patients with normal dopamine function.
Results: Total NMS burden, anxiety or depression did not differ between PD patients and patients with normal
DAT binding. DAT-normal patients reported more perception-related (p= 0.045) and attention/memory-related
NMSs than PD patients (p < 0.001). Total NMS score did not correlate with striatal DAT binding in either
group.
Conclusions: In clinically uncertain cases, the total NMS burden cannot be used as a tool in distinguishing PD
patients from patients with non-dopaminergic parkinsonism/tremor. Clinical screening of NMSs appears equally
important in all patients with parkinsonism.
1. Introduction
Patients with Parkinson's disease (PD) frequently sustain a multi-
tude of non-motor symptoms (NMSs), such as depression, hyposmia and
constipation, together with the classical motor symptoms [1]. NMSs
may affect the quality of life of PD patients even more than motor
symptoms [2]. Although there is a general consensus that NMSs are
prevalent in PD and some occur even at premotor stages, the specificity
of NMSs for PD is less clear. For example, NMSs are very common
symptoms among elderly individuals and patients with essential tremor
(ET) [3,4]. There is some evidence that dopaminergic pathophysiology
may underlie, at least partly, the majority of NMSs in PD [5]. However,
NMSs seem to also be common in subjects with scans without evidence
of dopaminergic deficits (SWEDDs), which underlines the complexity of
the issue [6].
To investigate the specificity and diagnostic value of NMSs in a
clinical setting, we examined NMSs in patients undergoing [123I]FP-CIT
single photon emission computed tomography (SPECT). We compared
NMSs in PD patients to those in patients with tremor or parkinsonism
but who have normal dopamine function.
2. Methods
2.1. Patients
Patients scanned using [123I]FP-CIT SPECT for clinically uncertain
parkinsonism/tremor in Turku University Hospital or Helsinki
University Hospital, Finland, during the years 2014–2017 were
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investigated (NMDAT study; ClinicalTrials.gov identifier:
NCT02650843) clinically 2–4 h before the scanning. The investigations
included a clinical interview, the Unified Parkinson's Disease Rating
Scale (MDS-UPDRS) part III, Mini-Mental State Examination (MMSE),
Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), a
single-question screen for REM sleep behaviour disorder (RBD) and the
Non-Motor Symptoms Scale (NMSS). All investigators had completed
the MDS-UPDRS Training Program and Exercise. Patients with an
MMSE score< 18 were excluded from the study.
The study was accepted by the local ethics committee and was
conducted according to the Declaration of Helsinki. Written informed
consent was obtained from all patients.
2.2. Scanning and image analysis
For the scanning methodology, see the Supplementary material.
2.3. Statistical analyses
IBM SPSS Statistics (version 24, SPSS Inc., Chicago, Illinois, USA)
was used for statistical analyses. The differences between the two
groups were calculated using either independent samples t-test, Mann-
Whitney U test or Chi-square test as appropriate. Bonferroni corrections
were applied for NMS total scores and separately for NMSS subscores.
Analyses were performed separately in patients without anti-
parkinsonian medication. Spearman correlations were used in ex-
amining the correlations between specific binding ratios (SBRs) and
other variables and the correlation between symptom duration and
NMSS total score. In addition, partial correlations were performed
when controlling for age, MDS-UPDRS motor score and MMSE score.
Log-transformations for variables with skewed distribution were per-
formed when applicable. Voxel-wise statistical analysis methods are
described in the Supplementary material.
3. Results
Out of patients with abnormal imaging outcome, only those with PD
as the final clinical diagnosis were included in this study (n=84).
Patients with normal dopamine transporter (DAT) (n=109) received
the following diagnoses after SPECT scanning: clinically uncertain
parkinsonian syndrome (CUPS) (n= 29), undetermined tremor
(n= 21), ET (n=18), drug-induced parkinsonism (n= 8), memory
disorder or Alzheimer's disease (n= 8), vascular parkinsonism (n=6),
dystonia (n= 3), psychogenic parkinsonism (n=3), other (n=7) or
not available (n= 6).
PD patients and DAT-normal patients did not differ in age, sex or
total motor symptom severity (Table 1). There were no significant
differences in total NMSS, BDI, BAI or RBD scores between PD patients
and DAT-normal patients (Table 1, Fig. 1A). Additionally, there were no
differences in the prevalence of depression or anxiety between the two
groups when cut-off scores for BDI and BAI were used (p > 0.10). PD
patients scored lower in NMSS perception (corrected p=0.045) and
NMSS attention/memory (corrected p < 0.001) subscales than the
DAT-normal group (Table 1). Odds ratio (95% C.I.) for having PD was
0.994 (0.988–1.000) for every point increase in total NMSS score.
Motor symptom duration was longer in DAT-normal patients than in PD
patients (p= 0.004), although it did not correlate with NMSS total
score in either group (p > 0.05).
Striatal SBRs correlated negatively with age in both groups, posi-
tively with the MMSE score in both groups and negatively with the
MDS-UPDRS motor score in PD patients (Supplementary Table 1).
However, there were no significant correlations between striatal SBRs
and NMSS total scores in either group (Supplementary Table 1).
Adjusting for age, UPDRS motor score or MMSE score did not change
the results (p > 0.05). In the voxel-wise whole brain analysis of PD
patients, there was no significant association between SBR and NMSS
total score.
The results remained the same when PD patients were compared to
patients with ET (p > .05). Out of 84 PD patients and 109 DAT-normal
patients, 25 (30%) and 8 patients (7%), respectively, were receiving
antiparkinsonian medications at the time of imaging. The results re-
mained the same when these patients were removed from the analysis
(NMSS total scores mean [SD] 56.1 [45.7] vs 72.8 [52.7], corrected
p= .26). In addition, there were no differences in NMSs between PD
Table 1
Main demographic and clinical characteristics and non-motor symptom scores in PD patients and in patients with normal DAT binding. Values are means (SD)
[range] or n.
PD (n= 84) Normal DAT (n= 109) Pa Pb
Demographics
Age (years) 65.3 (9.4) [41–82] 64.1 (12.1) [17–83] 0.875 –
Sex (male/female) 38/46 57/52 0.331 –
Motor symptom duration (months) 30.4 (44.6) [2–360] 53.0 (68.7) [3–360] 0.004 –
MDS-UPDRS motor score 38.4 (16.1) [10–73] 35.4 (16.1) [5–89] 0.205 –
H&Y 2.0 (0.9) [1–4] 2.1 (0.8) [0–5] 0.064 –
Non-motor symptoms
MMSE 27.1 (2.4) [19–30] 26.6 (2.3) [19–30] 0.052 0.260
Depression (BDI score) 8.4 (7.7) [0–44] 10.1 (9.1) [0–42] 0.276 1.0
Anxiety (BAI score) 11.1 (6.6) [2−33] 14.3 (9.3) [1–50] 0.042 0.210
RBD (yes/no) 23/57 30/74 0.989 1.0
NMSS total score 55.5 (46.1) [0−221] 71.4 (53.4) [5–222] 0.049 0.245
Cardiovascular 1.8 (3.3) [0−12] 3.2 (4.1) [0–15] 0.013 0.117
Sleep/fatique 12.2 (9.9) [0–36] 12.5 (10.1) [0–45] 0.861 1.0
Mood/cognition 11.7 (17.5) [0–72] 16.9 (21.5) [0–72] 0.081 0.729
Perception 0.35 (1.6) [0–12] 0.97 (2.4) [0–12] 0.005 0.045
Attention/memory 4.4 (6.5) [0−33] 10.1 (11.0) [0–36] < 0.001 <0.001
Gastrointestinal 3.5 (4.7) [0−21] 4.3 (6.7) [0−30] 0.592 1.0
Urinary 9.5 (10.3) [0–36] 8.9 (8.2) [0–36] 0.699 1.0
Sexual 3.3 (5.9) [0–24] 4.8 (6.8) [0–24] 0.091 0.819
Miscellaneous 8.3 (7.7) [0–28] 9.6 (10.3) [0–44] 0.815 1.0
PD=Parkinson's disease, MDS-UPDRS= the Movement Disorder Society Unified Parkinson's Disease Rating Scale, H&Y=Hoehn and Yahr scale, MMSE=Mini-
Mental State Examination, BDI= Beck Depression Inventory, BAI= Beck Anxiety Inventory, RBD=REM sleep behaviour disorder, NMSS=Non-Motor Symptoms
Scale.
a T- test or Mann-Whitney U test as appropriate or Chi-Square for categorical variables.
b Bonferroni-correction for 5 (MMSE, BDI, BAI, RBD, NMSS total score) or 9 (NMSS subscores) comparisons.
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patients with and without antiparkinsonian medications (NMSS total
scores mean [SD] 54.0 [47.8] vs 56.1 [45.7], corrected p=1.0).
4. Discussion
Our results show that the total burden of NMSs is equal between PD
patients and patients with similar motor symptoms but normal brain
dopamine function. NMS burden was also not associated with brain
dopamine function in PD patients who were mostly unmedicated and at
early stages of their disease.
Previous studies have demonstrated that NMSs are more prevalent
in PD than in healthy controls [7]. The current study is the first to
investigate NMS burden in patients with parkinsonism of uncertain
cause. Our results are supported by findings derived from the
Parkinson's Progression Markers Initiative (PPMI) cohort demonstrating
that the prevalence of NMSs is the same or higher in subjects with
SWEDDs compared to PD patients with the exception of hyposmia
[6,8]. In our study, the only NMSS subscores that differed between PD
and DAT-normal patients were related to dysfunctions in perception
and attention/memory, which were more common in DAT-normal pa-
tients. The reason for this finding is unclear and needs further ver-
ification, but the differences in subjective cognitive symptoms may
partially be related to the finding that PD patients with mild cognitive
impairment do not appear to correctly identify cognitive deficits that
they have [9]. Previous studies support also the finding that DAT
density is not associated with total NMS burden in PD [7,10]. Given
that the NMSS total score is a sum score (severity and frequency) of
various symptoms that likely do not have the same pathophysiological
Fig. 1. A. NMSS total score in PD patients and normal DAT patients. B. NMSS total score in patients with no dopaminergic medication. Relationship between mean
putamen SBR and C. age in PD patients, D. MDS-UPDRS motor score in PD patients, E. NMSS total score in PD patients and F. NMSS total score in normal DAT
patients. DAT=dopamine transporter, NMSS=Non-motor symptoms scale, NS=Not significant, MDS-UPDRS= the Movement Disorder Society Unified
Parkinson's Disease Rating Scale, PD=Parkinson's disease.
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basis, the present study cannot be interpreted to indicate that individual
NMSs are not dopamine dependent. Additionally, neurotransmitters
other than dopamine are involved in NMSs [1], and further studies
using different neurotransmitter ligands are needed to investigate this
issue in full. In addition, it should be noted that the definition of the
total NMS burden may not be the same in all studies. We defined the
total burden as the NMSS total score, whereas there are previous studies
that have used the number of different NMSs as the indicator of the
total NMS burden [11].
It should be noted that our PD patients had shorter motor symptom
durations than the controls. This finding is consistent with earlier stu-
dies [12], and the motor symptom duration did not correlate with total
NMSS score. The MDS-UPDRS part III (motor part) scores did not differ
between the two groups, a finding which may seem counterintuitive at
first glance. It is important to note, however, that DAT normal patients
were not healthy although they turned out to have normal DAT
binding. Instead, they had motor symptoms to the degree that they
were suspected to have PD and were referred for SPECT. Furthermore,
MDS-UPDRS was developed for PD, and the results concerning other
conditions may not reflect motor symptoms as accurately as in PD. We
have discussed some of these issues in our earlier report as well [13]. In
the interpretation of our results it is also important to note that the
study population included patients who were referred for DAT imaging
due to diagnostic uncertainty. Thus, although the sample reflects clin-
ical reality at SPECT imaging, it may not be representative of the typical
clinical population of patients with PD. Nevertheless, the total NMSS
scores in our PD patients were very similar to those reported in previous
NMSS PD studies [10,11], which suggests that the NMSS burden in our
PD patients was not particularly high or low. However, in all NMSS
studies, recall bias is a possible common source of error because NMSS
focuses on the non-motor symptoms during the previous month. It is
also noteworthy that we used a single-question screen for RBD, and
although it appears to provide a sensitive estimate of RBD diagnosis
[14], RBD can be most accurately diagnosed by full polysomnography
[15].
The findings of this study confirm that NMSs are prevalent in PD.
More importantly, they indicate that, as compared to PD patients, the
burden of NMSs is similar in clinically matched population of patients
without neurodegenerative parkinsonism syndromes. Total NMS load
thus does not seem to be useful for differential diagnostics and the re-
sults do not support a significant relationship between presynaptic
dopamine function and NMS burden. It is apparent that clinical NMS
screening is important also in patients with parkinsonism/tremor who
have normal brain dopamine function. The present findings also high-
light the importance of control population selection in PD NMS-trials
when making inferences for clinical practice.
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